Stock Comparison
JNJ vs SMMT
Johnson & Johnson vs Summit Therapeutics Inc
Who's the better investment? Let's break it down.
The Verdict
SMMT takes this one.
It's not even close. SMMT outscores JNJ by 7.7 points. That's a significant gap in our deep value framework.
Want to compare any two stocks?
Sign up free — get 3 DVR analyses/day, 1800+ stocks, portfolio roast. No credit card.
Valuation
JNJ
Metric
SMMT
Market Cap
P/E Ratio
Lower may indicate better value
Forward P/E
Price/Book
EV/EBITDA
Profitability & Growth
JNJ
Metric
SMMT
Profit Margin
Gross Margin
Operating Margin
Return on Equity
Return on Assets
Revenue Growth
EPS
Financial Health
JNJ
Metric
SMMT
Debt-to-Equity
Lower = less leverage
Current Ratio
Above 1.0 is healthy
Beta
Lower = less volatile
Dividend Yield
Risk Comparison
JNJ
What Could Go Wrong
The biggest risk for JNJ, despite its broad diversification, remains its exposure to patent expirations and increasing biosimilar competition for blockbuster drugs like Stelara, which generated over $...
Red Flags
- 🚩Deceleration of organic revenue growth below 4% for two consecutive quarters, signaling broader mark...
- 🚩Significant increase in litigation provisions or adverse judgments exceeding $5 billion in a single ...
- 🚩Dividend growth rate significantly slowing or pausing, indicating a fundamental shift in capital all...
SMMT
Competitive Moat
JNJ
Rating
🛡️ Wide
Trend
➡️ Stable
SMMT
Rating
🛡️ Narrow
Trend
📈 Expanding
Investment Thesis
If Johnson & Johnson continues to deliver consistent mid-single-digit organic revenue growth, driven by key pharmaceutical products and strategic MedTech innovation, while maintaining its strong dividend and capital allocation discipline, then its valuation should remain stable or grow modestly, providing a reliable long-term investment for income and capital preservation. This thesis focuses on s...
Full JNJ AnalysisSummit Therapeutics presents a compelling, high-risk, high-reward investment opportunity driven by ivonescimab's potential to become a blockbuster drug in the massive 2nd-line EGFR mutant NSCLC market. With critical regulatory and clinical catalysts approaching in 2026, strong leadership, and a differentiated mechanism, the company is strategically positioned for significant growth, provided it na...
Full SMMT AnalysisPrice Targets & Strategy
Price Targets & Entry/Exit Strategy
Sign up free to unlock the full comparison
Growth Catalysts
Growth Catalysts Comparison
Sign up free to unlock the full comparison
Market Sentiment
Market Sentiment Analysis
Sign up free to unlock the full comparison
The Deep Dive
Johnson & Johnson (JNJ) continues to demonstrate robust financial performance, with Q1 2026 results exceeding consensus on both revenue and adjusted EPS, reflecting nearly 10% YoY revenue growth. Its diversified healthcare portfolio provides significant market leadership and a wide economic moat, indicating stability and consistent profitability. However, its massive market capitalization of $555.59 billion fundamentally restricts its ability to achieve 10x growth within a 3-5 year timeframe. Su...
Full JNJ AnalysisSummit Therapeutics continues to hold significant 10x growth potential, primarily driven by its lead asset, ivonescimab, targeting the large US/EU non-small cell lung cancer (NSCLC) market. The bispecific mechanism provides a strong competitive advantage, and key regulatory milestones like the PDUFA date in November 2026 and HARMONi-3 interim data in Q2 2026 serve as major catalysts. The company maintains a robust cash position and positive free cash flow, supporting its clinical development. Ho...
Full SMMT AnalysisWant More Comparisons?
Run any stock through our deep value analyzer.
Not Financial Advice
This comparison is for educational purposes only. We are not financial advisors. Always do your own research and consult a qualified financial advisor before making investment decisions.